These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 6999801)

  • 1. Ultrastructure and viability of K. pneumoniae treated with fosfomycin.
    Schmid EN
    Zentralbl Bakteriol A; 1980 Aug; 247(3):339-46. PubMed ID: 6999801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viability and ultrastructure of S. aureus treated with fosfomycin.
    Schmid EN
    Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1983 Feb; 253(4):476-88. PubMed ID: 6858443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultrastructure and viability of E. coli treated fosfomycin.
    Schmid EN
    Zentralbl Bakteriol Orig A; 1979 Oct; 245(1-2):48-54. PubMed ID: 44623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of subinhibiting concentrations of fosfomycin on the ultrastructure of E. coli K 126].
    Carlone NA; Cattaneo O; Cuffini AM; Ferrero M
    G Batteriol Virol Immunol; 1980; 73(7-12):260-71. PubMed ID: 7030849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural changes induced by subinhibitory concentrations of fosfomycin on Staphylococcus aureus and Bacillus cereus.
    Carlone NA; Cuffini AM; Cattaneo O
    Microbios; 1982; 33(132):119-28. PubMed ID: 6810067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [In vitro activity of fosfomycin against ESBL-producing enterobacteria of urinary origin].
    Hernández MS; García JA; Muñoz JL
    Rev Esp Quimioter; 2009 Mar; 22(1):25-9. PubMed ID: 19308743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the Etest method for fosfomycin susceptibility of ESBL-producing Klebsiella pneumoniae.
    López-Cerero L; de Cueto M; Díaz-Guerrero MA; Morillo C; Pascual A
    J Antimicrob Chemother; 2007 Apr; 59(4):810-2. PubMed ID: 17289760
    [No Abstract]   [Full Text] [Related]  

  • 8. [Prerequisites for enhancement of the efficacy of fosfomycin by glucose-6-phosphate in treatment of experimentally infected animals (author's transl)].
    Hirschl A; Stanek G; Rotter M; Holzmann A; Frisch-Niggemeyer W; Laber G
    Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1981 Nov; 250(4):529-39. PubMed ID: 7036592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The value of fosfomycin].
    Tauchnitz C; Ezold R; Gonschorek J
    Z Gesamte Inn Med; 1982 May; 37(9):253-9. PubMed ID: 7048772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical studies and morphological response on ST-95 (fosfomycin)].
    Washida H; Watanabe H; Noguchi Y; Kato M; Tozawa K; Inuzuka K
    Hinyokika Kiyo; 1991 Mar; 37(3):321-6. PubMed ID: 2069116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diffusion of fosfomycin into bone tissue in man].
    Sirot J; Lopitaux R; Dumont C; Rampon S; Cluzel R
    Pathol Biol (Paris); 1983 Jun; 31(6):522-4. PubMed ID: 6348661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum sensitivity and cell surface hydrophobicity of Klebsiella pneumoniae treated with gentamicin, tobramycin and amikacin.
    Hostacká A
    J Basic Microbiol; 1998; 38(5-6):383-8. PubMed ID: 9871334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of fosfomycin alone and in combination with ceftriaxone or vancomycin in an experimental model of meningitis caused by two strains of cephalosporin-resistant Streptococcus pneumoniae.
    Ribes S; Taberner F; Domenech A; Cabellos C; Tubau F; Liñares J; Viladrich PF; Gudiol F
    J Antimicrob Chemother; 2006 May; 57(5):931-6. PubMed ID: 16507562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Fosfomycin].
    Gobernado M
    Rev Esp Quimioter; 2003 Mar; 16(1):15-40. PubMed ID: 12750755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. International collaborative study on standardization of bacterial sensitivity to fosfomycin.
    Andrews JM; Baquero F; Beltran JM; Canton E; Crokaert F; Gobernado M; Gomez-Ius R; Loza E; Navarro M; Olay T
    J Antimicrob Chemother; 1983 Oct; 12(4):357-61. PubMed ID: 6643331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in serum sensitivity and hydrophobicity in a clinical isolate of Klebsiella pneumoniae treated with subinhibitory concentrations of aminoglycosides.
    Hostacká A
    Zentralbl Bakteriol; 1998 Dec; 288(4):519-26. PubMed ID: 9987190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a Cys115 to Asp substitution in the Escherichia coli cell wall biosynthetic enzyme UDP-GlcNAc enolpyruvyl transferase (MurA) that confers resistance to inactivation by the antibiotic fosfomycin.
    Kim DH; Lees WJ; Kempsell KE; Lane WS; Duncan K; Walsh CT
    Biochemistry; 1996 Apr; 35(15):4923-8. PubMed ID: 8664284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptidoglycan synthesis and its fine chemical composition in dividing and not dividing Klebsiella pneumoniae cocci.
    Canepari P; Di Stefano CF; Lleò MM; Satta G
    New Microbiol; 1993 Apr; 16(2):165-70. PubMed ID: 8510570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of ciprofloxacin and levofloxacin in experimental pneumonia caused by Klebsiella pneumoniae deficient in porins, expressing active efflux and producing QnrA1.
    Rodríguez-Martínez JM; Pichardo C; García I; Pachón-Ibañez ME; Docobo-Pérez F; Pascual A; Pachón J; Martínez-Martínez L
    Clin Microbiol Infect; 2008 Jul; 14(7):691-7. PubMed ID: 18558942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.